收费全文 | 20650篇 |
免费 | 1579篇 |
国内免费 | 833篇 |
耳鼻咽喉 | 34篇 |
儿科学 | 344篇 |
妇产科学 | 194篇 |
基础医学 | 2146篇 |
口腔科学 | 159篇 |
临床医学 | 1669篇 |
内科学 | 3422篇 |
皮肤病学 | 196篇 |
神经病学 | 1040篇 |
特种医学 | 265篇 |
外科学 | 888篇 |
综合类 | 2478篇 |
现状与发展 | 1篇 |
预防医学 | 963篇 |
眼科学 | 133篇 |
药学 | 7150篇 |
7篇 | |
中国医学 | 1077篇 |
肿瘤学 | 896篇 |
2023年 | 145篇 |
2022年 | 250篇 |
2021年 | 485篇 |
2020年 | 542篇 |
2019年 | 491篇 |
2018年 | 546篇 |
2017年 | 551篇 |
2016年 | 643篇 |
2015年 | 583篇 |
2014年 | 1071篇 |
2013年 | 1696篇 |
2012年 | 1099篇 |
2011年 | 1219篇 |
2010年 | 1037篇 |
2009年 | 1007篇 |
2008年 | 1091篇 |
2007年 | 1091篇 |
2006年 | 978篇 |
2005年 | 904篇 |
2004年 | 869篇 |
2003年 | 798篇 |
2002年 | 640篇 |
2001年 | 515篇 |
2000年 | 508篇 |
1999年 | 471篇 |
1998年 | 366篇 |
1997年 | 371篇 |
1996年 | 314篇 |
1995年 | 291篇 |
1994年 | 243篇 |
1993年 | 202篇 |
1992年 | 213篇 |
1991年 | 185篇 |
1990年 | 168篇 |
1989年 | 162篇 |
1988年 | 141篇 |
1987年 | 129篇 |
1986年 | 114篇 |
1985年 | 158篇 |
1984年 | 170篇 |
1983年 | 84篇 |
1982年 | 98篇 |
1981年 | 86篇 |
1980年 | 66篇 |
1979年 | 35篇 |
1978年 | 49篇 |
1977年 | 48篇 |
1976年 | 39篇 |
1975年 | 23篇 |
1974年 | 34篇 |
The common marmoset (Callithrix jacchus) is a useful experimental animal to evaluate the pharmacokinetics of drug candidates. Cytochrome P450 (P450) 2B enzyme in marmoset livers has been identified; however, only limited information on the enzymatic properties and distribution has been available.
Marmoset P450 2B6 amino acids showed high sequence identities (>86%) with those of primates including humans and cynomolgus monkeys. Phylogenetic analysis using amino acid sequences indicated that marmoset P450 2B6 was closer to human and cynomolgus monkey P450 2B6 than to P450 2B orthologs of other species, including pigs, dogs, rabbits and rodents.
Quantitative polymerase chain reaction analysis using specific primers showed P450 2B6 mRNA predominantly expressed in livers among the five marmoset tissues, similar to those of humans and cynomolgus monkeys.
Marmoset P450 2B6 heterologously expressed in Escherichia coli membranes oxidized 7-ethoxycoumarin, pentoxyresorufin, propofol and testosterone, at roughly similar rates to those of humans and/or cynomolgus monkeys. A high capacity of marmoset P450 2B6 with propofol 4-hydroxylation (at low ionic strength conditions) with a low Km value was relatively comparable to that for marmoset livers.
These results collectively indicated a high propofol 4-hydroxylation activity of P450 2B6 expressed in marmoset livers.
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献Butyrylcholinesterase (BChE) is a serine esterase that plays a role in the detoxification of natural as well as synthetic ester-bond-containing compounds. Alterations in BChE activity are associated with a number of diseases. Cholinergic system abnormalities in particular are correlated with the formation of senile plaques in Alzheimer’s disease (AD), and administration of cholinesterase inhibitors is a common therapeutic approach used to treat AD.
Here, our aim was to study the interaction between BChE and fluoxetine.
Molecular docking simulations revealed that fluoxetine penetrated deep into the active-site gorge of BChE and that it was engaged in stabilizing noncovalent interactions with multiple subsites. In substrate kinetic studies, the Vm, Km, kcat and kcat/Km values were found to be 20.59?±?0.36?U mg?1 protein, 194?±?14?µM, 1.3?×?108?s?1 and 6.7?×?105?µM?1s?1, respectively. Based on inhibitory studies, fluoxetine appeared to inhibit BChE competitively, with an IC50 value of 104?µM and a Ki value of 36.3?±?4.7?µM.
Overall, both the low Ki value and the high number of BChE–fluoxetine interactions suggest that fluoxetine is a potent inhibitor of BChE, although in vivo mechanisms for the direct effects of BChE inhibition on various pathologies remain to be further investigated.
The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.
DLM, CPM and TPM were metabolised by human CYP2B6 and CYP2C19, with the highest apparent intrinsic clearance (CLint) values for pyrethroid metabolism being observed with CYP2C19. Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5. None of the pyrethroids were metabolised by CYP2A6, CYP2E1, CYP3A7 or CYP4A11.
DLM, CPM and TPM were metabolised by both human CES1 and CES2 enzymes.
Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol. TPM had the highest and CPM the lowest apparent CLint values for total metabolism (CYP and CES enzymes) per gram of adult human liver.
Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.